Medicare will cover Wegovy to reduce heart disease risk

Catch up with NBC News Clone on today's hot topic: Medicare Will Cover Wegovy Reduce Heart Disease Risk Rcna143479 - Health and Medicine | NBC News Clone. Our editorial team reformatted this story for clarity and speed.

The move could expand access to millions of Americans.
Get more newsMedicare Will Cover Wegovy Reduce Heart Disease Risk Rcna143479 - Health and Medicine | NBC News Cloneon

Medicare will provide coverage for Wegovy for patients with an increased risk of heart attack, stroke or other serious cardiovascular problems, an agency spokesperson said Thursday.

The decision, experts say, could grant millions of patients access to the popular yet expensive weight loss medication.

Medicare, which currently provides health insurance to more than 65 million people in the U.S., has long been barred from paying for weight loss drugs.

Earlier this month, however, the Food and Drug Administration expanded the approval for Wegovy, saying that it can be prescribed to people who are overweight or have obesity to reduce their risk of heart disease.

The change prompted the Centers for Medicare and Medicaid Services to consider coverage because reducing heart disease risk is a medically accepted use under federal law, the spokesperson said.

Medicare will still not cover Wegovy if it is only being used for weight management, the spokesperson said.

Medicaid, the federal health insurance program for people with low incomes, will also be required to cover Wegovy to reduce heart disease risk.

Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University, said Medicare providing coverage for Wegovy is “transformational.”

But doing so could undermine Medicare’s “financial stability,” Gostin said. The drug carries a list price of around $1,200 a month, and many patients will likely want a prescription.

A survey from the University of Michigan National Poll on Healthy Aging in December found about 3 in 4 older adults believe Medicare should cover weight loss medications.

A blog post from the Congressional Budget Office last October said that if Medicare did cover weight loss medications such as Wegovy, the net cost to the program “would be significant over the next 10 years.”

“There could be a slippery slope where Medicare ends up paying for the drug to be used for weight loss purposes,” Gostin said. “That would bankrupt Medicare and cause a taxpayer revolt.”

Juliette Cubanski, deputy director of the Medicare policy program at KFF, a nonpartisan group that studies health policy issues, said that while Medicare won't cover the drug solely for weight loss, many people with heart disease are overweight or have obesity.

“We could see Medicare patients with both conditions get coverage of this drug for its heart health benefits,” Cubanski said. “That’s potentially a big deal given the large demand for this drug even in the absence of many insurers covering it.”

The drug will be covered under Medicare Part D, which covers the cost of medications people take at home, the spokesperson said.

It’s not clear how private insurance companies that offer supplemental Part D coverage will respond, Cubanski said, noting that plans do have the ability to add new drugs to the list of drugs they cover in the middle of the year, “but given the cost of this drug, plans might not want to be the first movers.”

AdBlock Detected!
Please disable it to support our content.
×

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Joe Biden Campaign News - Politics and Government | NBC News Clone | Kamala Harris Vp Announcement - Politics and Government | NBC News Clone | Trump Indictment Latest - Politics and Government | NBC News Clone | Election Results Live - Politics and Government | NBC News Clone | Swing States Polling - Politics and Government | NBC News Clone | Debate Highlights - Politics and Government | NBC News Clone | Budget Approval 2025 - Politics and Government | NBC News Clone | Abortion Ruling - Politics and Government | NBC News Clone | Us China Relations - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Federal Reserve Interest Rates - Business and Economy | NBC News Clone | Stock Market Today - Business and Economy | NBC News Clone | Recession Prediction 2025 - Business and Economy | NBC News Clone | Jobs Report Unemployment - Business and Economy | NBC News Clone | Ai Stock Surge - Business and Economy | NBC News Clone | Housing Market Crash - Business and Economy | NBC News Clone | Oil Prices Update - Business and Economy | NBC News Clone | Amazon Prime Sales - Business and Economy | NBC News Clone | Bitcoin Etf Approval - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Covid Variants Update - Health and Medicine | NBC News Clone | Boosters New Guidelines - Health and Medicine | NBC News Clone | Anxiety Depression Treatment - Health and Medicine | NBC News Clone | Longevity Research - Health and Medicine | NBC News Clone | Diet Trends 2025 - Health and Medicine | NBC News Clone | Workout Routines - Health and Medicine | NBC News Clone | Fda Approvals 2025 - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Israel Palestine War News - World News | NBC News Clone | China Taiwan Tensions - World News | NBC News Clone | Middle East Peace Talks - World News | NBC News Clone | European Union Politics - World News | NBC News Clone | Development News - World News | NBC News Clone | North Korea Missile Test - World News | NBC News Clone | Brazil Election - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | Google Bard Ai - Technology and Innovation | NBC News Clone | Ai Regulation Laws - Technology and Innovation | NBC News Clone | Tiktok Ban Update - Technology and Innovation | NBC News Clone | Data Breaches 2025 - Technology and Innovation | NBC News Clone | Iphone 16 Release - Technology and Innovation | NBC News Clone | Nasa Mars Mission - Technology and Innovation | NBC News Clone | Web3 Developments - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Super Bowl 2025 Preview - Sports and Recreation | NBC News Clone | Nba Playoffs 2025 - Sports and Recreation | NBC News Clone | Champions League Finals - Sports and Recreation | NBC News Clone | World Series 2025 - Sports and Recreation | NBC News Clone | Masters Tournament 2025 - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hurricane Season 2025 - Weather and Climate | NBC News Clone | Global Warming Report - Weather and Climate | NBC News Clone | Weekly Weather Update - Weather and Climate | NBC News Clone | Earthquake Alerts - Weather and Climate | NBC News Clone | Solar Storm Warning - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Oscar Nominations 2025 - Entertainment and Celebrity | NBC News Clone | Grammy Awards 2025 - Entertainment and Celebrity | NBC News Clone | Netflix New Releases - Entertainment and Celebrity | NBC News Clone | Video Game Releases - Entertainment and Celebrity | NBC News Clone | Bestseller List - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Political Corruption - Investigations and Analysis | NBC News Clone | Big Tech Monopoly - Investigations and Analysis | NBC News Clone | Data Privacy Scandal - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone | Nyc Mayor News - Local News and Communities | NBC News Clone | La Wildfires Update - Local News and Communities | NBC News Clone | Hurricane Preparedness - Local News and Communities | NBC News Clone